Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 13/20 | 0.69 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502482 | 0.86 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL4510068 | 0.86 | CACNA1B (0.59) | CACNA1BCASR | |
| SCHEMBL7659273 | 0.85 | CACNA1B (0.68) | CACNA1B | |
| SCHEMBL6931116 | 0.85 | CACNA1B (0.58) | CACNA1BCASR | |
| SCHEMBL4496949 | 0.84 | CACNA1B (0.67) | CACNA1B | |
| SCHEMBL7656324 | 0.84 | CACNA1B (0.66) | CACNA1BSMN1; SMN2 | |
| SCHEMBL7669506 | 0.84 | CACNA1B (0.66) | CACNA1BSMN1; SMN2 | |
| SCHEMBL5415166 | 0.83 | CACNA1B (0.77) | CACNA1B | |
| SCHEMBL7663847 | 0.83 | CACNA1B (0.65) | CACNA1BSMN1; SMN2 | |
| SCHEMBL6929492 | 0.83 | CACNA1B (0.55) | CACNA1BCASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | AJINOMOTO CO., INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1318147-A1 | NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6350762-B1 | SELECTIVELY INHIBIT THE ACTION OF N-TYPE CALCIUM CHANNEL; | AJINOMOTO CO., INC. (JP) | 2002-02-26 | — | — | US | disclosed |
| CN-1283187-A | Novel dipydropyridine derivative | AJINOMOTO KK (JP) | 2001-02-07 | — | — | CN | disclosed |
| EP-1043314-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | CACNA1B 2/4885CASR 74/4885EPHX2 1239/4885 |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | CACNA1I, CACNA1B, CACNA1E | CACNA1B 2/4885CASR 134/4885EPHX2 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.